ArticlePloS one2012
The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- The Potential of MicroRNAs as Prostate Cancer Biomarkers.European urology · 2016Pooled it
- The role of microRNA in castration-resistant prostate cancer.Urologic oncology · 2014Pooled it
- MicroRNA-23b: Roles, functions and mechanisms in tumor.Genes & diseases · 2026Review
- Integrative analysis of urinary microRNAs for prostate cancer detection: A proof-of-concept study.Translational oncology · 2026Article
- MircoRNAs as regulators of regulated cell death in cancer progression: a focus on ferroptosis, anoikis and pyroptosis.Frontiers in pharmacology · 2026Review
- Exosomal miRNAs-a diagnostic biomarker acting as a guiding light in the diagnosis of prostate cancer.Functional & integrative genomics · 2022Review
- Small Nucleolar Derived RNAs as Regulators of Human Cancer.Biomedicines · 2022Review
- Non-coding RNAs and glioblastoma: Insight into their roles in metastasis.Molecular therapy oncolytics · 2022Review
- Knockdown of microRNA-214-3p Promotes Tumor Growth and Epithelial-Mesenchymal Transition in Prostate Cancer.Cancers · 2021Article
- MicroRNA-27b inhibits the development of melanoma by targeting MYC.Oncology letters · 2021Article
- A novel miRNA inhibits metastasis of prostate cancer via decreasing CREBBP-mediated histone acetylation.Journal of cancer research and clinical oncology · 2021Article
- microRNA-27b inhibits cell proliferation and invasion in bladder cancer by targeting engrailed-2.Bioscience reports · 2021Article
- High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer.Frontiers in oncology · 2021Article
- MiRNA-671-5p Promotes prostate cancer development and metastasis by targeting NFIA/CRYAB axis.Cell death & disease · 2020Article
- Coordinated AR and microRNA regulation in prostate cancer.Asian journal of urology · 2020Review
- MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer.Cancer drug resistance (Alhambra, Calif.) · 2020Article
- MicroRNAs are Necessary for BMP-7-induced Dendritic Growth in Cultured Rat Sympathetic Neurons.Cellular and molecular neurobiology · 2019Article
- Profiling and bioinformatics analyses of differential circular RNA expression in prostate cancer cells.Future science OA · 2018Article
- HOTAIR contributes to cell proliferation and metastasis of cervical cancer via targettingBioscience reports · 2018Article
- Long noncoding RNA TOB1-AS1, an epigenetically silenced gene, functioned as a novel tumor suppressor by sponging miR-27b in cervical cancer.American journal of cancer research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
MicroRNAs (miRs) are small, endogenous, non-coding RNAs that regulate the stability and/or translation of complementary mRNA targets. MiRs have emerged not only as critical modulators of normal physiologic processes, but their deregulation may significantly impact prostate and other cancers. The expression of miR-23b and miR-27b, which are encoded by the same miR cluster (miR-23b/-27b), are downregulated in metastatic, castration-resistant tumors compared to primary prostate cancer and benign tissue; however, their possible role in prostate cancer progression is unknown. We found that ectopic expression of miR-23b/-27b in two independent castration-resistant prostate cancer cell lines resulted in suppression of invasion and migration, as well as reduced survival in soft agar (a measure of anoikis). However, there was no effect of miR-23b/-27b on cell proliferation suggesting that these miRs function as metastasis (but not growth) suppressors in prostate cancer. Conversely, inhibition of miR-23b/-27b in the less aggressive androgen-dependent LNCaP prostate cancer cell line resulted in enhanced invasion and migration also without affecting proliferation. Mechanistically, we found that introduction of miR-23b/-27b in metastatic, castration-resistant prostate cancer cell lines resulted in a significant attenuation of Rac1 activity without affecting total Rac1 levels and caused increased levels of the tumor suppressor E-cadherin. Inhibition of these miRs had the opposite effect in androgen-dependent LNCaP cells. These results suggest that miR-23b/-27b are metastasis suppressors that might serve as novel biomarkers and therapeutic agents for castration-resistant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.